Revolutionary Weekly Insulin Awiqli Launched in India for Diabetes Management

Introduction to Awiqli

For individuals managing diabetes, the routine often involves multiple medications and daily insulin shots. However, a new treatment option is set to simplify this process significantly. Awiqli, known as insulin icodec, is the first-ever once-weekly basal insulin introduced in India by Novo Nordisk. This innovative approach allows eligible diabetes patients to administer just one injection per week instead of the usual seven. Experts believe this advancement could enhance treatment adherence and ease long-term diabetes management, especially for those who find daily injections challenging.

Understanding Awiqli

What is Awiqli?

Awiqli is formulated with insulin icodec, an ultra-long-acting basal insulin that ensures consistent blood sugar control throughout the week. Unlike conventional basal insulins that necessitate daily doses, Awiqli is administered just once every seven days. Dr. Shaival Chandalia, a Consultant Endocrinologist at Jaslok Hospital & Research Centre, explains that this medication primarily manages fasting blood glucose by fulfilling the body's basal insulin needs. He notes, "This novel once-a-week insulin reduces the frequency of injections and can enhance therapy adherence." This treatment is anticipated to benefit many adults with Type 2 diabetes who need basal insulin, as well as select patients with Type 1 diabetes under medical supervision.

Mechanism of Weekly Insulin

How Does Weekly Insulin Work?

The effectiveness of Awiqli stems from its unique formulation. Upon injection, insulin icodec attaches to albumin, a natural protein in the blood, allowing for a gradual and continuous release over a week. This mechanism helps maintain stable insulin levels, crucial for regulating fasting blood sugar. However, Dr. Chandalia emphasizes that this weekly insulin does not replace mealtime treatments. Patients may still need oral diabetes medications or rapid-acting insulin to manage post-meal blood sugar levels. He advises, "While it reduces the number of injections, it should be initiated with guidance from your healthcare provider, who will adjust the dosage and type of other diabetes medications accordingly."

Significance of Awiqli

Why is This a Breakthrough?

For many individuals with diabetes, maintaining a consistent treatment regimen poses significant challenges. Daily injections can lead to missed doses, fatigue from frequent shots, and inadequate blood sugar control. A once-weekly option like Awiqli could enhance medication adherence while alleviating the physical and psychological strain associated with daily injections. Novo Nordisk has priced Awiqli at approximately ₹261 per week, making it a more accessible option for eligible patients.

Who Can Benefit from Awiqli?

Who Can Benefit?

Healthcare professionals suggest that Awiqli may be appropriate for adults with Type 2 diabetes who require basal insulin, select individuals with Type 1 diabetes under specialist care, and those who find daily insulin injections burdensome. The decision to initiate weekly insulin therapy should always be made by a healthcare provider after assessing the patient's medical history and current treatment plan. Dr. Chandalia warns, "Patients must be aware of the usual risks, such as hypoglycemia, which can occur with other insulins as well."

Potential Risks of Awiqli

Are There Any Risks?

As with all insulin therapies, Awiqli carries a risk of hypoglycemia (low blood sugar) if not used properly. Patients transitioning to weekly insulin may need to adjust their existing diabetes medications, including oral drugs and short-acting insulin. Experts strongly recommend against altering insulin regimens without medical supervision. Dr. Chandalia is optimistic about the future, suggesting that combining once-weekly insulin with weekly GLP-1 receptor agonists could eventually provide comprehensive blood sugar control with just one weekly injection, improving management of both fasting and post-meal glucose levels. While not suitable for everyone, this innovative therapy marks a significant advancement in simplifying diabetes management.